SCHEMBL103814

SCHEMBL103814

CO[C@@H]1O[C@@H](CO)[C@@H](O[C@@H]2OC(CO)[C@@H](O[C@@H]3O[C@@H](CO)[C@@H](C)C(O)C3NC(C)=O)[C@H](O)C2NC(C)=O)C(O)C1NC(C)=O

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 8/20 0.56
LGALS7; LGALS7B P47929 3/20 0.56
LGALS1 P09382 1/20 0.56
LGALS9 O00182 3/20 0.54
LGALS8 O00214 2/20 0.53
LGALS4 P56470 1/20 0.53
CD69 Q07108 1/20 0.50
CHIA Q9BZP6 1/20 0.49
ALDH1A1 P00352 1/20 0.46
THRB P10828 1/20 0.46
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13123120 0.95 LGALS3 (0.53) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL27272247 0.94 LGALS3 (0.55) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL17954599 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL13136604 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL16675413 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL10023255 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL17953133 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL13799095 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL15386146 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8
SCHEMBL13784257 0.91 LGALS3 (0.58) LGALS3LGALS7; LGALS7BLGALS1LGALS9LGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9414967-B2 Composition, preparation, and use of chitosan shards for biomedical applications LOMA LINDA UNIVERSITY (US) 2016-08-16 US disclosed
US-9364578-B2 Hemostatic agent for topical and internal use LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 2016-06-14 US disclosed
US-20160121021-A1 COMPOSITION, PREPARATION, AND USE OF CHITOSAN SHARDS FOR BIOMEDICAL APPLICATIONS UNIV LOMA LINDA (US) 2016-05-05 US disclosed
US-20160082037-A1 COMPOSITION, PREPARATION, AND USE OF CHITOSAN POWDER FOR BIOMEDICAL APPLICATIONS LOMA LINDA UNIVERSITY MEDICAL CENTER 2016-03-24 US disclosed
US-20160058904-A1 CHITOSAN-BASED HEMOSTATIC TEXTILE NORTH CAROLINA STATE UNIVERSITY 2016-03-03 US disclosed
US-9259357-B2 Composition, preparation, and use of chitosan shards for biomedical applications LOMA LINDA UNIVERSITY (US) 2016-02-16 US disclosed
US-20160030025-A1 VASCULAR WOUND CLOSURE DEVICE AND METHOD LOMA LINDA UNIVERSITY MEDICAL CENTER 2016-02-04 US disclosed
US-9226988-B2 Chitosan-based hemostatic textile LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 2016-01-05 US disclosed
US-20150297783-A1 COMPOSITION, PREPARATION, AND USE OF CHITOSAN SHARDS FOR BIOMEDICAL APPLICATIONS NORTH CAROLINA STATE UNIVERSITY 2015-10-22 US disclosed
US-20150086419-A1 CHITOSAN-BASED HEMOSTATIC TEXTILE LOMA LINDA UNIVERSITY MEDICAL CENTER 2015-03-26 US disclosed
US-8932521-B2 Chitosan-based hemostatic textile LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 2015-01-13 US disclosed
US-20140178446-A1 HEMOSTATIC AGENT FOR TOPICAL AND INTERNAL USE LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 2014-06-26 US disclosed
US-8623274-B2 Chitosan-based hemostatic textile LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 2014-01-07 US disclosed
US-20120093686-A1 CHITOSAN-BASED HEMOSTATIC TEXTILE LOMA LINDA UNIVERSITY MEDICAL CENTER 2012-04-19 US disclosed
US-20120059410-A1 WOUND CLOSURE DEVICE AND METHOD LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160082037-A1 COMPOSITION, PREPARATION, AND USE OF CHITOSAN POWDER FOR BIOMEDICAL APPLICATIONS CHIT1, NCDN, CHIA LGALS3 1377/4885LGALS7; LGALS7B 1697/4885LGALS1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.